Brief: Genfit SA - Advances Nangibotide In Phase 2 Clinical Investigation In Aclf
14/09/2026 17:18
BRIEF-Genfit SA - Advances Nangibotide In Phase 2 Clinical Investigation In Aclf Sept 14 (Reuters) - Genfit SA GNFT.PA:
GENFIT - NANGIBOTIDE TO ENTER PHASE 2A ACLF STUDY IN Q4 2026, DATA IN 2027
ADVANCES NANGIBOTIDE IN PHASE 2 CLINICAL INVESTIGATION IN ACLF
NANGIBOTIDE SHOWS STATISTICALLY SIGNIFICANT REDUCTION IN MORTALITY IN SEVERE COVID-19
NANGIBOTIDE DEMONSTRATES FAVORABLE SAFETY PROFILE ACROSS FOUR CLINICAL TRIALS
Source text: nNDL3NcdYm
Further company coverage: GNFT.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Genfit SA
See all newsFrance's Genfit H1 revenue falls due to absence of milestone payments
French and Benelux stocks-Factors to watch on September 15
Brief: Genfit SA - Advances Nangibotide In Phase 2 Clinical Investigation In Aclf
Brief: Euronext Includes Genfit, Inventiva In SBF120 Index; Interparfums, Verallia Excluded
Brief: Genfit March 31 Cash And Cash Equivalents EUR 136.1 Million